The embryonal carcinoma P19 model has allowed the elucidation of a role for several transcription factors in cell differentiation. Here, the regulation of the RNA polymerase II machinery has been explored through its association with multifunctional complexes involved in transcription. An interaction proteomics analysis of TFIIS-purified RNA polymerase II (RNAPII) holoenzymes during cardiomyogenesis is described. Modifications of protein complexes that may be associated with transcriptionally active and activator responsive RNAPII holoenzymes were detected in a serum and DMSO dependent manner. Subunits of the PAF1 and Mediator complexes were correlated with holoenzymes from non-differentiated and terminally differentiated P19 cultures respectively. Moreover, high levels of nucleolin were identified in all forms of holoenzymes by two-dimensional gel electrophoresis, and suggest that nucleolin could bind to RNAPII and TFIIS. Several proteins that were identified in the RNAPII holoenzymes are known to have functions in mRNA processing and may bind to nucleolin. A novel function for nucleolin is proposed as a possible pivotal platform between transcription, mRNA processing and export.
Introduction
The embryonal carcinoma P19 cell line is a model system for the study of cell differentiation programs [1] [2] [3] . Under appropriate external stimuli, P19 cells differentiate into neurons and astrocytes following retinoic acid exposure [4] , or into mesodermal and muscle cells following dimethyl sulphoxide (DMSO) exposure [5] . Several transcription factors implicated in P19 cardiomyocyte differentiation have been shown to play major roles in the cardiomyogenesis pathway [2] . The transcription factors GATA-4, Nkx2.5 and MEF2c constitute a self amplifying genetic system leading to cardiac commitment [2] . In turn, transcription factors are involved in the recruitment of RNA polymerase II (RNAPII) to the genes' promoter for transcription to occur.
The minimal assembly of RNAPII for the initiation of transcription consists of core RNA polymerase II and a set of general transcription factors (TFIID, TFIIB, TFIIF, TFIIE, TFIIH), in sequential events of preinitiation complex formation, promoter clearance, elongation and termination [6, 7] . The regulation of transcription is very complex and depends also on chromatin structure [8, 9] . One possible level of regulation is the formation of RNAPII with other proteins into a preassembled RNAPII holoenzyme. The RNAPII holoenzyme consists of core RNA polymerase II, general transcription factors and a multimeric complex, referred to as Mediator [10] . The composition of the multimeric complex associated with the holoenzyme is believed to be modified in response to activators, repressors and nuclear hormone receptors [7, 11, 12] . For example, RNAPII forms different holoenzymes capable of receiving and integrating cellular signals or modifing chromatin structure [13] . The diversity of complexes that interact with RNAPII span a vast spectrum of functions in transcription, genomic maintenance and splicing [14] [15] [16] [17] [18] [19] .
Several methods of RNAPII holoenzyme purification have been described which lead to the differential loss of components [12, 20] . Pan et al. (1997) reported the use of the elongation factor TFIIS in the purification of human holoenzyme [21] . Their gentle technique allowed the recovery of a mixture of transcriptionally active RNAPII holoenzymes (Mr 2.4 MDa) containing all the general transcription factors from HeLa cells [12] . The protein composition of the different TFIIS-purified holoenzymes from HeLa cells was shown to consist of subunits from the spliceosome [19] and to vary according to cell cycle [22] . The changes in protein composition of TFIIS-purified holoenzymes during cell differentiation have not been addressed. In this study, modifications in RNAPII holoenzymes during cardiomyocyte differentiation were explored using the murine P19 cell line. Transcriptionally active murine RNAPII holoenzymes obtained using the human TFIIS elongation factor [21] were characterized by proteomics.
Experimental procedures

Cell culture and differentiation
All cell culture products were obtained from Invitrogen (Canada). HeLa S3 cell suspensions (American Type Culture Collection, USA) were grown exponentially in RPMI medium 1640 supplemented with 5% newborn bovine serum. HeLa cell suspensions were inoculated at a population density of 1 × 10 5 cells/ml and harvested three days later at a cell density of 5 × 10 5 /ml. Cells were centrifuged at 4 000 g and frozen at −70
The P19 teratocarcinoma cell line was offered by Dr. R. St.-Arnaud (Shriners Hospital for Children, Canada) and grown in α-Minimal Essential Medium supplemented with 2.5% fetal bovine serum (FBS) and 7.5% calf serum (CS). Non-differentiated (Nd) P19 cells were inoculated in tissue culture dishes at a cell density of 1×10 5 /ml and subcultured every second day using 0.05% trypsin-EDTA. P19 cells were induced to differentiate in bacteriological-grade petri dishes at a cell density of 1 × 10 5 /ml in the presence of 1%
DMSO. Efficient induction of cardiomyogenesis was obtained without the screening or selection of serum lots, but instead by alternating fetal bovine and calf serums as shown in Figure 1 . Cell aggregates (Agg.) subcultured twice over a period of four days, were then washed in culture medium and transferred at a 1:10 ratio to tissue culture dishes in the absence of DMSO. Cells were then maintained for six days with medium renewal every second day. At different steps of the procedure, cells were centrifuged at 1000g and frozen at 70
• C. All cell cultures and holoenzyme preparations (see below) were repeated in at least 5 biological replicates.
Fig. 1
Culture scheme for P19 cardiomyocyte differentiation. Non-differentiated (Nd) P19 cells were grown in adherent conditions. For the induction of differentiation with 1% dimethyl sulphoxide (DMSO), cells were grown in suspension conditions in order to allow cell aggregation (Agg). The alternating of calf (CS)-fetal bovine (FBS) serum to fetal only serum in the culture medium, as shown at this stage of culture, determined whether P19 cells differentiated into precursor cardiomyocytes (Cc) or beating cardiomyocytes (Bc). Detailed protocol is described in the Methods section.
Purification of RNA polymerase II holoenzymes
Whole cell extracts (WCE) were prepared as previously described [21] . Briefly, 5 g of cells were thawed on ice, homogenized in extraction buffer and centrifuged at 37K for three hours at 4
• C. The WCE was then dialyzed against 2 l of ACB buffer (50 mM NaCl, 10 mM
Hepes, pH 7.9, 0.1 mM EDTA, 0.1 mM dithiothreitol, 10% glycerol), centrifuged 20 min at 30K and frozen at 70 • C. All chemicals were obtained from Sigma Aldrich (Canada).
RNAPII holoenzyme purification was as described previously [21] . The plasmids expressing the GST or GST-TFIIS fusion proteins were a gift from Dr. J. Greenblatt (University of Toronto, Canada). Briefly, GST and GST-TFIIS fusion protein were obtained from transformed DH5α bacteria, and GST or GST-TFIIS glutathione Sepharose 4B columns were prepared according to manufacture's protocol (GE Healthcare Life Sciences, Canada). The size of the columns was 0.5 ml and single used. A column was loaded with 10 column volumes of WCE, and then washed with 10 column volumes of ACB buffer containing 50 mM NaCl. Proteins were eluted into 200 μl fractions using 2 column volumes of ACB buffer containing 300 mM NaCl. Protein concentration was determined by the Bradford method (BioRad, Canada) and samples immediately frozen at 70
• C. The holoenzyme complex eluted from the GST-SII affinity column was further separated by size exclusion (Superose 6 HR 10/30, GE Healthcare Life Sciences, Canada) in ACB buffer containing 50 mM NaCl and 20% glycerol as previously described [19] .
In vitro transcription assay
In vitro transcription assay was performed as previously described [19] . Transcription was initiated from adenovirus type 2 major late promoter on the plasmid GML33, derived from plasmid pML (C2AT)-50 [23] . The reaction mixture (20 μl [21] was added to the reaction mixture. After one hour incubation at 30
200 μl of stop solution was added to the mixture followed by acid phenol-chloroform RNA extraction. Transcripts were separated in a 4% acrylamide, 8M urea gel and exposed 10 hours on BioMax MS film with intensifying screen (Kodak) at −70
Activation of transcription was analyzed by primer extension assay as described [25] . Briefly, after in vitro transcription without [32P] UTP, the extracted transcripts were washed in 70% ethanol and dried. Transcripts were then dissolved in hybridization buffer with 0.1 pmole of primer (GGAATAATGAGGTTTAAAGGAGAGTAGGGTG) previously labeled with γ32P-ATP using T4 kinase (USB Corporation, USA). After 1 hour incubation at 55
• C, the hybridized transcripts were precipitated with isopropanol, washed in 70% ethanol and dried. Pellets were then dissolved in 10 μl of TRIS (10 mM, pH 7.8) and 10 μl of extension buffer containing 5 units of AMV Reverse Transcriptase (Promega, Canada). After 1 hour incubation at 45
• C, the reactions were denatured at 94
• C for 2 minutes in formamide loading buffer and then separated on a 10% acrylamide, 5 M urea gel. The dried gel was then exposed on a PhosphoImager screen for 12 hours and levels of cDNA were detected and quantified using a Storm PhosphorImager (GE Healthcare Life Sciences, Canada).
Two-dimensional gel electrophoresis and immunoblotting
For two-dimensional (2D) gel electrophoresis analysis, holoenzymes where separated either by isoelectric focusing (IEF) [26] or by non-equilibrium pH gradient electrophoresis (NEpHGE) [27] . IEF was prepared with 2% Pharmalyte 4-10 and ran for 14000 V×hr, whereas NEpHGE was prepared with 6% Pharmalyte 4-10 (GE Healthcare Life Sciences, Canada) and ran for 2800 V×hr. Proteins were analyzed in 10% SDS-PAGE (BioRad) and silver stained as described [28] . For mass spectrometry analysis, 2D gels were stained by Coomassie blue (Sigma, Canada) and protein spots (including negative control samples) were processed for mass-spectrometry (MALDI-TOF) analysis at the Eastern Quebec Proteomics Centre (Canada). Briefly, samples were reduced and the cysteine residues alkylated, followed by in-gel digestion by trypsin. Protein identification was obtained from the mass spectrometric peptide mapping data using the ProFound search engine [29] .
The search was performed in dalton unit (Da) within the NCBInr (2005) database of the Rodentia category (http://prowl.rockefeller.edu/profound bin/WebProFound.exe), using specifications of 0 to 1 missed trypsin cleavage, iodoacetamide (Cys) modification and charged MH+ state. For immunoblot analysis, proteins were separated in 7.5 or 12.5% SDS-PAGE, followed by wet immunoblotting without methanol (BioRAD, Canada). Immunoblot staining was done according to manufacture's ECL protocol (GE Healthcare Life Sciences, Canada). Antibodies 8WG16 and N-20 directed against Rpb1 subunit of RNAPII were obtained from BAbCO (USA) and Santa Cruz (USA) respectively. Antibody F-18 directed against nucleolin was obtained from Santa Cruz (USA). Polyclonal antibodies directed against TBP, TFIIB, TFIIF (RAP30), TFIIE (α, β) were provided by Dr. J. Greenblatt (University of Toronto, Canada) and monoclonal antibodies directed against TFIIH subunits were provided by Dr. J.M. Egly (Institut de Génétique et de Biologie Moléculaire et Cellulaire, France). Antibodies directed against hnRNP A1 and H were provided by Dr. B. Chabot (University of Sherbrooke, Canada) and by Dr. D. Black (University of California) respectively. Blots were scanned and digitized by UN-SCAN-IT (Silk Scientific, USA).
Results
P19 cardiomyogenesis
The teratocarcinoma derived P19 cell line has a high proliferation rate and was subcultured every second day at a 1:4 split ratio (i.e. Non-differentiated, Nd; Figure 1 ). Once transferred to bacteriological-grade petri dishes, P19 cells formed spherical aggregates (Agg.) of embryogenic appearance, a necessary step for differentiation to occur [2, 3] . Cell aggregates were treated with 1% DMSO in order to induce the mesodermal/endodermal pathway. On the fifth day of culture, treated aggregates were then plated in differentiating culture conditions (adherent condition) without DMSO.
Factors in serum may inhibit both P19 neurogenesis [30] or cardiomyogenesis [31] . In order to avoid the necessity to screen for non-inhibitory serum lots for terminal differentiation, a highly reproducible method for P19 differentiation was found by alternating the ratio of FBS and CS. Cell aggregates were cultured in the presence of 10% FBS for the induction step (Figure 1 ), and then into 2.5% FBS-7.5% CS in differentiating culture conditions. Cell aggregates cultured in constant 2.5% FBS-7.5% CS did not produce beating cardiomyocytes, but instead precursor cardiomyocytes (Cc). In contrast, cell aggregates cultured in the presence of 10% FBS, later differentiated into beating cardiomyocytes (Bc). It took 4 days after transfer to differentiating culture conditions for cells to differentiate into beating cardiomyocytes (Supplemental Figure 1) .
The percentage of cardiomyocytes in cultures using cardiac markers, such as GATA-4 and Nkx2-5 was not determined since the observation of beating cardiomyocytes was deemed a sufficient indication of terminal differentiation. Although the P19 model has the disadvantage of producing several different cell lineages, the presence of terminally differentiated and beating cardiomyocytes permitted the comparison of holoenzymes obtained from non-differentiated and differentiated P19 cardiomyocyte (see below).
3.2 Murine RNA polymerase II holoenzymes P19 cells at different stages leading to beating cardiomyocytes were used to identify modifications in the composition of RNAPII holoenzymes during cell differentiation (Figure 2) . Purification of the murine RNAPII holoenzyme using human TFIIS was comparable to the holoenzymes obtained using human HeLa cells, as previously described [19] . Both human and murine complexes eluted at the same concentration (0.5 μg/ml) and elution time using 300 mM NaCl. Importantly, the eluted murine complex separated as a single peak by size exclusion chromatography (Figure 2A ). The size of the murine complex was estimated to be 2.3 MDa. Moreover, the murine holoenzymes specifically bound to TFIIS and not to control glutathione S-transferase (GST) sepharose 4B columns. As shown, only a few faint peptides were observed from the elution of the negative control GST-column, with no transcriptional activity or proteins detected by immunoblot as described below (data not shown). Abbreviations are the same as in Figure 1 .
Both human and murine holoenzyme preparations showed comparable SDS-PAGE polypeptide patterns ( Figure 2B ). Likewise, all murine holoenzymes obtained from the different culture conditions appeared to have similar profiles. Slight polypeptide modifications in holoenzymes were noticeable, such as the disappearance of a peptide estimated at 94 kDa in DMSO treated cell aggregates (Agg DMSO). Polypeptide pattern of holoenzymes from Cc differentiating culture conditions revealed the absence of a 74 kDa peptide and appearance of a 26 kDa peptide. Holoenzymes from beating cardiomyocytes (Bc) displayed additional proteins, with estimated molecular mass of 84, 71, and 27 kDa (lane 6).
The similar level of detection of the large subunit of RNAPII (Rpb1) by immunoblot (pol IIA, Figure 2C ), suggests that all holoenzyme preparations contained comparable amounts of core RNAPII. General transcription factors (GTF) such as TFIIB, F, E and H were equally detected in both the human and murine holoenzymes and appeared to be present in stoichiometric amounts. The decrease in detection of the β subunit of TFIIE (34 kDa) in Bc holoenzymes was variable, and levels in subsequent Bc preparations were comparable to Nd holoenzymes (not shown). The large subunit of TFIIF (RAP74) followed the same detection pattern as the RAP30 subunit of TFIIF (data not shown). Antibodies directed against all the subunits of human TFIIH [32] were tested, however only the antibodies specific for the subunits p52 and p62 recognized murine TFIIH.
The capacity of the murine holoenzymes to accurately initiate in vitro transcription was analyzed on a DNA template containing the adenovirus major late promoter placed upstream of a G-less cassette (Figure 3 ). Holoenzyme preparations were compared using equal amounts of total protein (2 μg), and transcription reactions were supplied with yeast TATA-binding protein (TBP) as it had been previously shown to be in substoichiometric amounts in the human holoenzyme [21] . In fact, murine holoenzymes had little detectable endogenous TBP (data not shown). The basal transcription activity of the murine holoenzyme from non-differentiated cells (Nd) was comparable to the holoenzymes purified from precursor cardiomyocytes (Cc). Relative to holoenzymes from HeLa (H) cells, holoenzymes purified from beating cardiomyocytes (Bc) had a lower transcription activity of 0.4-fold as compared to 0.7-fold for Nd or Cc holoenzymes. In contrast to the other preparations that showed a positive correlation between the amount of holoenzymes and level of transcription activity, higher amounts of Bc holoenzymes did not produce higher activity (Supplemental Figure 2) .
Bc holoenzymes were nevertheless responsive to transcriptional activation by GAL4-VP16, with fold activation in transcription comparable to Nd and H holoenzymes from non-differentiated P19 cells or control HeLa cells respectively (Figure 3) . The capacity to initiate transcription by the different holoenzymes was not related to the phosphorylation state of the C-terminal domain (CTD) of the large RNAPII subunit Rpb1, since all holoenzyme preparations had no detectable phosphorylated CTD (i.e. Pol IIO; Figure 3 ). Increasing the amount of TBP in the assay significantly improved the activity of both basal and activated transcription of Bc holoenzymes (Supplemental Figure 2) . However, the possible specificity of Bc holoenzymes for cardiomyocyte gene promoter templates was not tested here. Relative transcription (Tx) activity of the different holoenzymes was compared to transcription activity levels of HeLa holoenzymes set as 1. C. Activation of transcription using the activator GAL4-VP16 is shown by a plus sign. Fold activation was compared to nonactivated primer extension levels set at 1. Abbreviations are the same as in Figure 1 . The results are representative of more than five independent experiments.
Proteomics of murine RNAPII holoenzymes
The different holoenzyme preparations obtained from three types of P19 cells (Nd, Cc and Bc) were separated by two-dimensional (2D) gel electrophoresis (Figure 4) . Purified holoenzymes were analyzed by IEF, however basic proteins were also resolved by NEpHGE. All holoenzyme preparations produced very similar 2D profiles with small differences in the intensity of a few spots between preparations. Nd holoenzymes had a larger proportion of negatively charged proteins of high molecular weight (IEF gel), whereas positively charged proteins of high molecular weight appeared in Cc and Bc holoenzymes (NEpHG gel). The 2D profiles were consistent and reproducible between holoenzyme preparations from at least five biological repeats.
Predominant spots preferentially observed in either Nd, Cc and Bc were identified by mass spectrometry and reported in Table 1 . The reported protein spots were also detected in the single peak after size exclusion chromatography as shown in Figure 2 (data not shown). The large spots (numbers 6, 7 & 8) detected in Cc holoenzymes and to a lesser extent in the other holoenzymes were identified as nucleolin ( Table 1 ). The presence of nucleolin in the holoenzymes was validated by immunoblotting ( Figure 5 ). The difference in the size of spots for nucleolin in the 2D gels did not correlate with its immunodetection in the different holoenzyme preparations. Possible modifications in total charge of the protein, perhaps by phosphorylation [33] , may have altered its migration in the 2D gels between different holoenzyme preparations. Nonetheless, the three isoforms of nucleolin identified by proteomics in the murine holoenzymes was validated by immunoblot analysis.
Finally, hnRNP H was also validated by immunoblot ( Figure 5 ), and showed a concomitant decrease in detection in Cc holoenzymes in both 2D profile and immunoblot. The presence of the polypyrimidine tract binding protein PTB (hnRNP I), the counterpart of PSF (Table 1) , was also detected in all holoenzyme preparations (data not shown). The difference in holoenzymes composition from beating cardiomyocytes was confirmed by the detection of a presumably smaller isoform of hnRNP A1.
Discussion
The purification of RNAPII holoenzymes by TFIIS affinity chromatography [21] was used here to identify regulatory subunits that may possibly be associated with the transcription machinery during P19 cardiomyogenesis. An efficient method to obtain terminally differentiated P19 cells was described, which then permitted the comparison of holoenzymes from cycling and terminally differentiated cells. In this study, different holoenzymes that occur during the cell cycle [22] of non-differentiated cells (i.e. Nd) were not characterized. Moreover, the P19 model produces several cell lineages in culture which may have reduced the detection of modifications specifically associated with terminally differentiated cardiomyocytes. Despite this limitation, the effect of DMSO and serum was shown here to influence not only differentiation, but also to alter the polypeptide composition of holoenzymes. Table 1 Interaction proteomics of RNA polymerase II holoenzymes during P19 cardiomyogenesis. Abbreviations: hnRNP, heterogeneous nuclear ribonucleoprotein; PTB, polypyrimidine tract binding protein; TRAP, thyroid hormone receptor-associated protein.
Estimated molecular weight (MW) and theoretical isoelectric points (pI) are reported. Interestingly, the murine RNAPII holoenzymes underwent a progressive decline in basal transcription activity associated with terminally differentiated cardiomyocytes. The decrease in transcription activity was not related to the absence of GTFs or phosphorylation state of the CTD of Rpb1 [34] . All holoenzymes responded to the transcription activator GAL4-VP16, thus confirming the present of the Mediator in all holoenzyme preparations [21, 35] . Importantly, the modulation of the mediator complexes during cardiomyogenesis was shown with the preferential detection of two subunits of the Mediator complex, Crsp3 [36] and Thrap1 [37] in Bc holoenzymes.
The reason for the reduced basal transcription activity of holoenzymes from terminally differentiated cells is unknown. This contrasts with the high basal transcription activity of holoenzymes purified from non-differentiated P19 cells (or HeLa cells). The low basal transcription activity from differentiated P19 cardiomyocytes suggests that gene specific RNAPII holoenzyme complexes may prevail in terminally differentiated cells. The possible specificity of the Bc holoenzyme for myogenic gene promoters, perhaps by a combinatorial assembly mechanism [38] , warrants further investigation.
The regulation of cell cycle progression at the level of RNAPII holoenzymes in cycling P19 cells (Nd) was suggested by the identification of leo1-like protein, an analogue subunit of the yeast PAF1 complex [39] . Moreover, the presence of the cancer marker hnRNP F [25] and hnRNP A/B [40] decreased in differentiated Bc holoenzymes as compared to Nd holoenzymes. This is consistent with the fact that differentiated P19 cells are non-tumorigenic as opposed to non-differentiated P19 cells [41] , and suggests that holoenzymes from cycling or tumorigenic cells may be lacking regulatory subunits.
The identification of nucleolin in the holoenzymes of HeLa and P19 cells cast doubt on the true nature of TFIIS-purified holoenzymes. Different isoforms of nucleolin have been previously reported [42] , and in this study three isoforms were identified in the mouse holoenzymes. At the transcriptional level, nucleolin was shown to be a subunit of a RNA polymerase II complex [43] , to stimulate transcription [44] and to have chromatin remodeling activity [9] . Nucleolin is also a polyfunctional RNA-binding factor involved in the stabilization and export of mRNA with several different heterogeneous nuclear ribonucleoproteins (hnRNP) [45] [46] [47] . Here, the majority of polypeptides that were identified by proteomics (Table 1) have functions in mRNA processing and may bind to nucleolin (i.e. hnRNP). Nucleolin as well as hnRNP A1 could also have other implications in the assembly and activity of RNAPII similar to their roles reported for the formation of the telomerase complex [48, 49] . In this regard, it is interesting to note that hnRNP I and PSF were detected in the RNAPII holoenzymes, and may further implicate nucleolin in CTD-dependent mRNA processing [50] .
The biological significance of nucleolin within the TFIIS-purified holoenzymes is beyond the scope of the present study. The elongation factor TFIIS has multiple functions in the initiation of transcription, elongation and mRNA cleavage [51, 52] , and is also associated with cajal bodies [53] . Cajal bodies are organelles which comprise the transcriptome and spliceosome [54, 55] , and importantly also contain nucleolin [54] . The amount of nucleolin detected in the holoenzymes suggests that it could also bind to TFIIS, and perhaps function as a pivotal platform between transcription, splicing, mRNA processing and export [56] . Taken together, this report offers new perspectives in the regulation of P19 cardiomyogenesis at the level of RNAPII. The possible interaction of nucleolin with RNAPII and TFIIS, and its role in the coordination of transcription, mRNA processivity and export remains to be explored.
